-
Clinical Outcomes by Tumor Mutational Burden and Inflammatory Gene Expression With Combined Nivolumab and Ipilimumab or Monotherapy in Advanced Melanoma - CM67 WES
Study
EGAS00001004555
-
Regulatory T cell transcriptomic reprogramming characterizes adverse events by checkpoint inhibitors in solid tumors
Study
EGAS00001004694
-
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard and high risk myeloma
Study
EGAS00001004558
-
RNASeq of PDX and CDX tumours treated with ADC
Study
EGAS00001004562
-
Clinical Outcomes by Tumor Mutational Burden and Inflammatory Gene Expression With Combined Nivolumab and Ipilimumab or Monotherapy in Advanced Melanoma
Study
EGAS00001004564
-
Clinical Outcomes by Tumor Mutational Burden and Inflammatory Gene Expression With Combined Nivolumab and Ipilimumab or Monotherapy in Advanced Melanoma - CM066-WES
Study
EGAS00001004567
-
Single cell RNA sequencing of CD19 CAR T-cell infusion products
Study
EGAS00001004576
-
Whole Exome Sequences from Iberian Roma samples
Study
EGAS00001004599
-
Queensland Melanoma Genomic Biomarker Study
Study
EGAS00001004619
-
Mutational landscape of eccrine porocarcinoma (sweat gland tumour)
Study
EGAS00001004632
-
RNA sequencing of follicular T cell lymphoma
Study
EGAS00001004646
-
Targeted sequencing of Burkitt lymphoma tumour samples from the UK's Haematological Malignancy Research Network
Study
EGAS00001004649
-
Cerebrospinal fluid circulating tumour DNA allows the characterisation and monitoring of medulloblastoma
Study
EGAS00001004651
-
Tumour gene expression signature in primary melanoma predicts long-term outcomes: A prospective multicentre study
Study
EGAS00001004664
-
Lymphoma Group
Dac
EGAC00001001243
-
Ultraviolet radiation drives mutations in a subset of mucosal melanomas
Study
EGAS00001004697
-
A novel orthotopic patient-derived xenograft model of radiation-induced glioma following medulloblastoma
Study
EGAS00001004709